- Home
- ALUB vs CLLS Comparison
ALUB vs CLLS Comparison
Compare ALUB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.92
Company Overview
Basic Information| Metric | ALUB | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 384.3M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALUB | CLLS |
|---|---|---|
| Price | $10.00 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 59.2K | 30.4K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.33 |
| 52 Week High | $10.10 | $5.48 |
Technical Indicators
Market Signals| Indicator | ALUB | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 52.69 |
| Support Level | $9.98 | $3.39 |
| Resistance Level | $10.04 | $4.48 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 53.85 | 23.17 |
Price Performance
Historical Comparison ALUB
CLLS
About ALUB Alussa Energy Acquisition Corp. II Class A Ordinary Shares
Alussa Energy Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.